SEC Form 4 · accession 0001140361-16-069193
BIOMARIN PHARMACEUTICAL INC · BMRN
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
A later amendment supersedes this filing — read the amendment. The figures below are kept as originally reported (version chain, not an overwrite).
Reporting owner
V Bryan Lawlis
Director
Period of report
Jun 6, 2016
Accepted (ET)
Jun 8, 2016 · 8:02 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001048477
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Jun 6, 2016 | A | 1,510 | $0.00 | A | 14,410 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to buy) Common StockF2 | $89.52 | Jun 6, 2016 | A | 4,440 | A | Jun 6, 2017 | Jun 5, 2026 | Common Stock | 4,440 | 4,440 | D |
Explanation of responses
- F1Restricted stock units granted on June 6, 2016. Price not applicable.
- F2Option grant vests in full on June 6, 2017.